United States

Advanced Search

per page
  Report Title Date Provider Type Pgs Price

Orexo AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

29 Oct 2016 Reuters Investment Profile 12 $20.00

Orexo AB: Upgraded to Below Average

02 Nov 2016 Sadif Analytics Prime 3 $10.00

Wright Investors Service Comprehensive Report for Orexo Ab

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

22 Oct 2016 Wright Reports 69 $75.00

Orexo - Good things come in threes

Orexo has delivered on three key newsflow items, which should contribute to driving increased Zubsolv use in the treatment of...

07 Oct 2016 Edison Investment Research 3 $10.00

Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review

Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review Summary Orexo AB (Orexo) is an emerging specialty pharmaceutica...

06 Sep 2016 GlobalData 69 $300.00


Orexo’s Q216 results pointed to positive Zubsolv momentum with evidence of net revenue growth, improving margins and encourag...

10 Aug 2016 Edison Investment Research 10 $10.00

Will Orexo AB Deliver Long-Term Returns?

08 Aug 2016 Sadif Analytics Prime 12 $25.00

Orexo AB: Downgraded to Risky

02 Aug 2016 Sadif Analytics Prime 3 $10.00

ORX.ST - Event Transcript of Orexo AB conference call, Jul. 12, 2016 / 8:00AM ET

Edited Event Transcript of ORX.ST conference call, Jul. 12, 2016 / 8:00AM ET Boston, Jul 12, 2016 (Thomson StreetEvents...

12 Jul 2016 Thomson Reuters StreetEvents 13 $75.00


Mundipharma has licensed exclusive global ex-US rights to Zubsolv. Deal terms include a €7m upfront payment, in addition to f...

04 Jul 2016 Edison Investment Research 2 $10.00